此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

舒尼替尼和帕唑帕尼治疗晚期或转移性肾细胞癌的治疗药物监测 (SUP-R)

2026年11月17日 更新者:Institut Claudius Regaud

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study.

Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib).

The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

研究概览

研究类型

介入性

注册 (实际的)

47

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bordeaux、法国、33076
        • Institut Bergonie
      • Bordeaux、法国、33035
        • CHU DE BORDEAUX - Hôpital Saint-André
      • Limoges、法国、87042
        • CHU DE LIMOGES - Hôpital Dupuytren
      • Lyon、法国、69373
        • Centre Leon Berard
      • Marseille、法国、13273
        • Institut Paoli Calmettes
      • Montpellier、法国、34298
        • Institut Regional Du Cancer Montpellier
      • Rodez、法国、12027
        • CH RODEZ
      • Toulouse、法国、31059
        • Institut Claudius Regaud

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma.
  2. Measurable tumours as defined by RECIST criteria version 1.1.
  3. Age ≥ 18 years old.
  4. WHO Performance Status ≤ 2.
  5. Life expectancy ≥ 6 months.
  6. Adequate cardiac function (baseline Left Ventricular Ejection Fraction (LVEF) ≥ 50% determined by Multiple Gated Acquisition scan (MUGA) or echocardiography) and pulmonary function.
  7. Renal function defined as creatinine clearance (Cockcroft and Gault formula) > 30 mL/min.
  8. Adequate liver function defined as: total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN); Alanine AminoTansferase (ALAT) and Aspartate AminoTransferase (ASAT) ≤ 2.5 x ULN; Concomitant elevation in bilirubin and ASAT/ALAT above 1.0 x ULN is not allowed.
  9. Patients must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up.
  10. Negative pregnancy test for women in childbearing potential.
  11. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study (before study entry and until 30 days after the last administration of study treatment).
  12. Patients affiliated to a social health insurance.

Exclusion Criteria:

  1. Patients without any venous access for blood sampling.

  2. Hypersensitivity to the active substance or to any of the excipients.

  3. History or clinical evidence of central nervous system (CNS) metastases, except for individuals who have previously-treated CNS metastases.

  4. Corrected QT interval (QTc) > 480msecs using Bazett's formula.

  5. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to:

    • Uncontrolled infection.
    • Cardiovascular conditions within the last 6 months such as cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New-York Heart Association (NYHA), clinically significant irregular heartbeat requiring medication.
    • Poorly controlled hypertension [defined as systolic blood pressure of ≥140 mmHg or diastolic pressure of ≥90 mmHg).
    • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months.

    Note: patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.

  6. Evidence of active bleeding or bleeding diathesis.

  7. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cytochrome P450 isoenzyme 3A4 (CYP3A4) within the last 14 days prior to inclusion and/or during the study.

  8. Patients already treated with an anticancer treatment in the previous four weeks or patient requiring anticancer treatment during the study (chemotherapy, immunotherapy, hormonotherapy, radiotherapy or surgery).

  9. Pregnant or breast-feeding women.

  10. Positive diagnostic of HIV, B and C hepatitis.

  11. Patients with serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety, provision of informed consent, or compliance to study procedures.

  12. Patients who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Pazopanib

The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).

During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.

有源比较器:Sunitinib

Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).

During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
第一部分:药代动力学 - 帕唑帕尼或舒尼替尼血浆浓度
大体时间:在第 1 周期和第 2 周期的第 1 天和第 15 天(周期长度为 6 周)
在第 1 周期和第 2 周期的第 1 天和第 15 天(周期长度为 6 周)
第二部分:疗效 - 1 年时无进展的患者比例。这对应于每组患者总数中 1 年时无进展的患者数量
大体时间:5.5年
5.5年
第一部分:根据 NCI 毒性量表(4.03 版)的不良事件
大体时间:1.5年
1.5年
Part II: Tolerance - Proportion of patients without treatment discontinuation due to adverse event (AE) during the first year.
大体时间:5.5 years

This corresponds to the number of patients without treatment discontinuation due to AE among the total number of patients in each group.

5.5 years

次要结果测量

结果测量
措施说明
大体时间
第 I 和 II 部分:根据 NCI 分类的安全性:不良反应通用毒性标准 (CTCAE) 4.03 版。
大体时间:5.5年
5.5年
Part I and II: Objective Response (e.g. Complete or Partial Response)
大体时间:5.5 years

Objective Response will be defined using RECIST Criteria version 1.1.

5.5 years
Part I and II:- Progression free survival.
大体时间:5.5 years

Progression free survival is defined as the time from inclusion until progression (RECIST Criteria version 1.1) or death. Patients alive at last follow-up news are censored at this date.

5.5 years
Part I and II: Hand-foot syndrome (HFS)
大体时间:5.5 years

Hand-foot syndrome (HFS) will be evaluated using the HFS-14 questionnaire. This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment.

5.5 years
Part I and II: Quality of life using the quality of life questionnaire (QLQ)-C30
大体时间:5.5 years

Quality of life will be evaluated using the QLQ-C30 questionnaire

5.5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Christine CHEVREAU, MD、IUCT-O

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年11月17日

初级完成 (实际的)

2020年1月16日

研究完成 (实际的)

2020年1月16日

研究注册日期

首次提交

2015年9月4日

首先提交符合 QC 标准的

2015年9月21日

首次发布 (估计的)

2015年9月22日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅